Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s
Patients from a small phase 2a study saw their ADAS-Cog11 scores improve by 4.4 points
Biotech company Annovis Bio has revealed positive results for its lead investigational therapeutic ANVS401 in Alzheimer’s disease (AD) and Parkinson’s disease (PD).
The results come from a small phase 2a study evaluating ANVS401 in 14 AD patients and 14 PD patients.
The results show that patients treated with ANVS401 for 25 days achieved statistically significant cognitive improvement, measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11).
Specifically, patients in the ANVS401-treated group saw their ADAS-Cog11 scores improve by 4.4 points from baseline until 25 days – an improvement of 30%.
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer s Disease - Patients Cognition Improved 3 3 Points on ADAS-Cog11
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Annovis Bio, Inc : Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer s Disease - Patients Cognition Improved 3 3 Points on ADAS-Cog11
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Lilly s donanemab slowed Alzheimer s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
in vitro and
in vivo (APPswe/PS1dE9 mouse model of Alzheimer’s disease) experiments that show increased mast cell hemichannel activity after treatment with amyloid peptide (Ab
25–35), with subsequent degranulation response and enhanced histamine release [2]. The number of mast cells in hippocampal and cortical areas increased drastically even before amyloid plaque deposits became evident, suggesting that mast cells are one of the first brain cells to recognize and respond to amyloid peptides, and thus may play a critical role in the onset and progression of Alzheimer’s disease. Treatment with masitinib was shown to totally prevent the amyloid-induced hemichannel-dependent mast cell activity in bone marrow-derived mast cells and brain mast cells. The authors concluded that hemichannel expressed by mast cells might serve as a molecular target with which to develop therapeutic treatments that could delay the onset and progression of Alzheimer’s disease.